ArticleLasers in medical science2026
Photobiomodulation at 830 nm with 5 J/cm
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway regulates cell survival, proliferation, and the synthesis of protein. Photobiomodulation (PBM) stimulates biological processes by using low-powered light in the visible, red and near-infrared (NIR) spectrum. Despite its demonstrated efficacy, the cellular and molecular consequences, primarily on the PI3K/AKT/mTOR pathway, remain unclear. This study investigated PBMs impact on the PI3K/AKT/mTOR pathway in fibroblast (WS1) cells modelled as normal (N), wounded (W), hyperglycemic (D), hyperglycemic wounded (DW), and hyperglycemic hypoxic wounded (DHW). Non-irradiated cells served as controls. PBM was applied using an 830 nm diode at 5 J/cm2. Cellular changes at 24 and 48 h post-PBM were assessed via the Trypan blue exclusion assay (viability), light microscopy (morphology and migration), flow cytometry (proliferation and apoptosis), and the enzyme linked immunosorbent assay (ELISA) and western blot (VEGF, Bcl-2, PI3K, AKT, mTOR and GSK3β). PBM enhanced cellular migration rate, viability, and proliferation, without altering the PI3K/AKT/mTOR pathway. PBM at 830 nm with 5 J/cm2 promoted wound healing independently of the PI3K/AKT/mTOR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.